Table 3.
Studies of Exogenous Administration of SOD/CAT or SOD Overexpression in Respiratory Distress Syndrome Patients or Hyperoxic Lung Injury Models
| Patients or models | Administration details | Principal outcomes | Ref. |
|---|---|---|---|
| Rats, hyperoxic | IV liposome-encapsulated bovine SOD and CAT | Increased survival rate | (174) |
| Reduced pleural effusion | |||
| Rats, hyperoxic | ET liposome-encapsulated bovine SOD and CAT | Increased survival rate | (113) |
| Reduced lung histological abnormalities | |||
| Piglets, hyperventilated and hyperoxic | ET rhSOD | Reduced neutrophils chemotactic activity, total cell count, elastase activity, and albumin in TA | (37) |
| 5 mg/kg | |||
| Rabbits, lungs challenged with xanthine and xanthine oxidase | ET liposome-encapsulated bovine SOD and CAT | Preserved lung filtration coefficient | (15) |
| Preterm infants (n=26) | ET rhSOD | Reduced neutrophil chemotactic activity and albumin in TA (high dose) | (135) |
| BW 750–1250 g | 0.5 or 5 mg/kg within 30 min of surfactant, single dose | ||
| <24 h of life | |||
| Preterm infants (n=33) | ET rhSOD | Reduced neutrophil chemotactic activity and albumin in TA | (34, 36) |
| BW 700–1300 g | 2.5 or 5 mg/kg within 2 h of surfactant, up to 7 doses | Reduced wheezing requiring bronchodilators or steroids at 1 year follow up | |
| <24 h of life | |||
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression | Reduced lung neutrophils and oxidized GSH | (4) |
| Increased alveolar surface and lung volume density | |||
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression | Preserved alveolar and bronchiolar epithelium proliferation | (14) |
| Reduced DNA damage | |||
| Preserved apical protein expression in type I cells | |||
| Rabbit, hyperoxic | Transfection with hSOD3 containing plasmid, AER | Increased lung cGMP | (3) |
| Decreased lung NF-κB expression | |||
| Transgenic mice, hyperoxic | Lung-targeted SOD3 overexpression+IP Antileukinate for 7 days | Reduced lung neutrophils, 8-isoprostane and oxidized GSH | (102) |
| Reduced myeloperoxidase activity in TA |
TA, tracheal aspirate; IV, intravenous; ET, endotracheal; IP, intraperitoneal; AER, aerosolized; GSH, glutathione; rhSOD, recombinant human SOD; NF-κB, nuclear factor kappa B.